Search

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To explore the expression of recombinant human sequence similarity family 189 member B (FAM189B, alias COTE1) in hepatocellular carcinoma tissues and its correlation with the prognosis of hepatocellular carcinoma patients. Methods: Collect 59 patients undergoing radical resection of hepatocellular carcinoma, take their hepatocellular carcinoma tissues and adjacent tissues, use immunohistochemistry to detect COTE1 expression, analyze the relationship between COTE1 expression and clinicopathological parameters, and use Kaplan-Meier survival curve The relationship between COTE1 expression and patient prognosis was analyzed, and the COX proportional hazard regression model was used to analyze the prognostic factors. Results: The results of immunohistochemistry showed that 37 cases of COTE1 were highly expressed in hepatocellular carcinoma tissues, and COTE1 was highly expressed in 24 cases of adjacent tissues. The expression rate of COTE1 in hepatocellular carcinoma tissues was significantly higher than that in adjacent tissues (P< 0.05); COTE1 expression is correlated with alpha-fetoprotein (AFP) value and tumor recurrence (P<0.05), but has nothing to do with age, gender, and tumor size (P>0.05). Kaplan-Meier curve analysis found that patients with hepatocellular carcinoma with high COTE1 expression had a shorter postoperative survival period (P<0.05). COX proportional hazard regression analysis found that COTE1 expression can be an independent risk factor affecting the prognosis of patients with hepatocellular carcinoma (P<0.05). Conclusion: The expression of COTE1 in hepatocellular carcinoma tissues is higher than that in adjacent tissues. COTE1 expression can be used as an independent factor to predict the prognosis of patients with hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]

In 2015, the World Health Organization's classification of lung cancer proposed the concept of spread through air spaces (STAS) as a new model for lung adenocarcinoma invasion. STAS refers to the spread of lung cancer cells through the airways in the lung parenchyma beyond the edge of the main tumor. In recent years, with the deepening of STAS research, the results show that STAS as an invasive method is related to other invasive behaviors and metastasis. STAS is closely related to the prognosis of lung cancer and is also independently associated with the risk of recurrence. Notably, the prognosis of STAS-positive patients varies greatly with the choice of surgical methods. In imaging, STAS has its own special imaging features that can be used as a tool for estimating STAS likelihood. Therefore, whether it is possible to determine the presence or absence of STAS by imaging and other methods could become a significant guidance for selecting surgical methods and improving patients' prognosis. This review will focus on the recent research on the association of STAS with imaging, gene mutations, and different types of lung cancer. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)